Trends in cannabis or cocaine-related dependence and alcohol/drug treatment in Argentina, Chile, and Uruguay.
Argentina
Cannabis dependence
Chile
Cocaine dependence
Drug treatment
Uruguay
Journal
The International journal on drug policy
ISSN: 1873-4758
Titre abrégé: Int J Drug Policy
Pays: Netherlands
ID NLM: 9014759
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
received:
07
10
2021
revised:
09
07
2022
accepted:
19
07
2022
pubmed:
9
8
2022
medline:
13
10
2022
entrez:
8
8
2022
Statut:
ppublish
Résumé
In the context of changing cannabis and other drug policy and regulation, concerns may arise regarding drug treatment access and use. We assessed cannabis/cocaine-related dependence and treatment in Argentina, Chile, and Uruguay. Nationally representative cross-sectional household surveys of people ages 15-64 in Argentina (4 surveys, 2006-2017), Chile (7 surveys, 2006-2018), and Uruguay (4 surveys, 2006-2018) were harmonized. We estimated weighted prevalences of cannabis or cocaine-related (cocaine or cocaine paste) dependence, based on meeting 3+ past-year ICD-10 dependence criteria. We estimated weighted prevalences of past-year alcohol/drug treatment use (Argentina, Chile) or use/seeking (Uruguay) among people with past-year cannabis/cocaine-related dependence. We tested model-based prevalence trends over time and described individual-level treatment correlates by country. Cannabis/cocaine dependence prevalence increased in the region starting in 2010-2011, driven by cannabis dependence. Adjusted cannabis dependence prevalence increased from 0.7% in 2010 to 1.5% in 2017 in Argentina (aPD=0.8, 95% CI= 0.3, 1.2), from 0.8% in 2010 to 2.8% in 2018 in Chile (aPD=2.0, 95% CI= 1.4, 2.6), and from 1.4% in 2011 to 2.4% in 2018 in Uruguay (aPD=0.9, 95% CI= 0.2, 1.6). Cocaine-related dependence increased in Uruguay, decreased in Argentina, and remained stable in Chile. Among people with past-year cannabis/cocaine dependence, average alcohol/drug treatment use prevalence was 15.3% in Argentina and 6.0% in Chile, while treatment use/seeking was 14.7% in Uruguay. Alcohol/drug treatment prevalence was lower among people with cannabis dependence than cocaine-related dependence. Treatment correlates included older ages in all countries and male sex in Argentina only. Alcohol/drug treatment use among people with cannabis/cocaine-related dependence remained low, signaling an ongoing treatment gap in the context of growing cannabis dependence prevalence in the region. Additional resources may be needed to increase treatment access and uptake. Future studies should assess contributors of low treatment use, including perceived need, stigma, and service availability.
Sections du résumé
BACKGROUND
In the context of changing cannabis and other drug policy and regulation, concerns may arise regarding drug treatment access and use. We assessed cannabis/cocaine-related dependence and treatment in Argentina, Chile, and Uruguay.
METHODS
Nationally representative cross-sectional household surveys of people ages 15-64 in Argentina (4 surveys, 2006-2017), Chile (7 surveys, 2006-2018), and Uruguay (4 surveys, 2006-2018) were harmonized. We estimated weighted prevalences of cannabis or cocaine-related (cocaine or cocaine paste) dependence, based on meeting 3+ past-year ICD-10 dependence criteria. We estimated weighted prevalences of past-year alcohol/drug treatment use (Argentina, Chile) or use/seeking (Uruguay) among people with past-year cannabis/cocaine-related dependence. We tested model-based prevalence trends over time and described individual-level treatment correlates by country.
RESULTS
Cannabis/cocaine dependence prevalence increased in the region starting in 2010-2011, driven by cannabis dependence. Adjusted cannabis dependence prevalence increased from 0.7% in 2010 to 1.5% in 2017 in Argentina (aPD=0.8, 95% CI= 0.3, 1.2), from 0.8% in 2010 to 2.8% in 2018 in Chile (aPD=2.0, 95% CI= 1.4, 2.6), and from 1.4% in 2011 to 2.4% in 2018 in Uruguay (aPD=0.9, 95% CI= 0.2, 1.6). Cocaine-related dependence increased in Uruguay, decreased in Argentina, and remained stable in Chile. Among people with past-year cannabis/cocaine dependence, average alcohol/drug treatment use prevalence was 15.3% in Argentina and 6.0% in Chile, while treatment use/seeking was 14.7% in Uruguay. Alcohol/drug treatment prevalence was lower among people with cannabis dependence than cocaine-related dependence. Treatment correlates included older ages in all countries and male sex in Argentina only.
CONCLUSION
Alcohol/drug treatment use among people with cannabis/cocaine-related dependence remained low, signaling an ongoing treatment gap in the context of growing cannabis dependence prevalence in the region. Additional resources may be needed to increase treatment access and uptake. Future studies should assess contributors of low treatment use, including perceived need, stigma, and service availability.
Identifiants
pubmed: 35939947
pii: S0955-3959(22)00226-2
doi: 10.1016/j.drugpo.2022.103810
pmc: PMC9912990
mid: NIHMS1868944
pii:
doi:
Substances chimiques
Hallucinogens
0
Ethanol
3K9958V90M
Cocaine
I5Y540LHVR
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
103810Subventions
Organisme : NIDA NIH HHS
ID : K01 DA045224
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA040924
Pays : United States
Organisme : NIDA NIH HHS
ID : T32 DA031099
Pays : United States
Informations de copyright
Copyright © 2022. Published by Elsevier B.V.
Déclaration de conflit d'intérêts
Declarations of Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
J Stud Alcohol Drugs. 2009 Jul;70(4):516-27
pubmed: 19515291
Drug Alcohol Depend. 2021 Sep 1;226:108828
pubmed: 34325282
Lancet Infect Dis. 2016 Dec;16(12):1385-1398
pubmed: 27665254
Epidemiol Psychiatr Sci. 2020 Aug 04;29:e148
pubmed: 32746958
Soc Psychiatry Psychiatr Epidemiol. 2015 Sep;50(9):1317-26
pubmed: 26006253
JAMA Netw Open. 2021 May 3;4(5):e218049
pubmed: 33961037
Neuropsychopharmacology. 2018 Jan;43(1):195-212
pubmed: 28853439
Addiction. 2021 Oct;116(10):2600-2609
pubmed: 33651441
Eur Addict Res. 2021;27(6):413-427
pubmed: 33965941
Int J Drug Policy. 2017 Apr;42:118-120
pubmed: 28366597
Drug Alcohol Depend. 2017 Nov 1;180:401-416
pubmed: 28982092
Front Psychiatry. 2021 Mar 02;12:634515
pubmed: 33762979
Arch Gen Psychiatry. 2002 Jan;59(1):77-84
pubmed: 11779286
Drug Alcohol Depend. 2015 Apr 1;149:136-44
pubmed: 25725934
Drug Alcohol Depend. 2019 Aug 1;201:115-126
pubmed: 31207452
World Psychiatry. 2017 Oct;16(3):299-307
pubmed: 28941090
Addiction. 2021 Oct;116(10):2611-2613
pubmed: 34036659
Clin Psychol Sci. 2016 Nov;4(6):1028-1046
pubmed: 28008372
Lancet. 2012 Jan 7;379(9810):55-70
pubmed: 22225671
Addiction. 2020 Nov;115(11):2089-2097
pubmed: 32196789
JAMA Psychiatry. 2020 Sep 1;:
pubmed: 32870241
Stat Med. 2000 Feb 15;19(3):335-51
pubmed: 10649300
Curr Opin Psychiatry. 2017 Sep;30(5):378-388
pubmed: 28700360
Neuropsychopharmacology. 2018 Jan;43(1):173-194
pubmed: 28875989
Front Psychiatry. 2021 Apr 29;12:639393
pubmed: 34025471
Drug Alcohol Depend. 2011 Jan 15;113(2-3):88-95
pubmed: 20828942
Addiction. 2021 Oct;116(10):2615-2616
pubmed: 34184339
Cochrane Database Syst Rev. 2016 May 05;(5):CD005336
pubmed: 27149547
Epidemiol Psychiatr Sci. 2019 Aug 27;29:e53
pubmed: 31452485
Braz J Psychiatry. 2019 May-Jun;41(3):238-244
pubmed: 30427387
Sci Adv. 2019 Oct 16;5(10):eaax1532
pubmed: 31663022